CDKN2A and Familial prostate cancer: While E6AP appears to have a pro-oncogenic function, a few papers support a tumor-suppressive function for E6AP in breast and prostate cancers (Srinivasan and Nawaz, 2011; Levav-Cohen et al., 2012; Ramamoorthy et al., 2012; Mansour et al., 2016) and in non-small cell lung cancer where depletion of E6AP contributes to a decreased expression of the INK4/ARF locus (Gamell et al., 2017).